The agency’s staff analysis suggests that approval of the illegal drug known as Ecstasy for treatment of PTSD is far from certain, with advisers meeting next week to consider the proposed therapy. By ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window FDA staff raised ...

A panel of experts advising the Food and Drug Administration on the use of the psychedelic MDMA for post-traumatic stress disorder found on Tuesday that the available evidence fails to show that the ...

This photo provided by the Center for Psychedelic Therapy Research shows a Yehuda Lab MDMA-assisted therapy treatment room at the James J. Peters Department of Veterans Affairs Medical Center in the ...

MDMA (3,4-methylenedioxymethamphetamine), known colloquially as Molly and Ecstasy, is a synthetic drug with effects similar to stimulants like methamphetamine. It was first synthesized in 1912 by ...

A panel of advisers to the U.S. health regulator on Tuesday voted against a therapy based on the party drug MDMA for patients with post-traumatic stress disorder, in a major setback to the nascent ...

An FDA advisory committee on Tuesday voted against midomafetamine (MDMA) as an adjunct to psychotherapy in post-traumatic stress disorder (PTSD). In a 9-2 vote, the Psychopharmacologic Drugs Advisory ...

Share on Pinterest A key FDA panel voted down approving MDMA-assisted therapy to treat PTSD. pixdeluxe/Getty Images An expert panel of the Food and Drug Administration reviewed two studies on ...

When making regulatory decisions about a drug, the U.S. Food and Drug Administration (FDA) often relies on advisory committees to provide independent advice. (U.S. Food & Drug Admin., Learn About FDA ...

Learn about the drug that may have taken two lives at a music festival. Sept. 3, 2013— -- If you listen to electronic music, you’re probably familiar with molly. Molly is basically the same as ...

MDMA-assisted therapy may provide lasting benefit for patients with MDD. Seven-month follow-up shows sustained symptom ...

In a surprisingly strong rejection of the first psychedelic therapy to come before the Food and Drug Administration, a scientific advisory panel on Tuesday overwhelmingly voted against the use of MDMA ...